Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of SCD I: A First in Human Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of MTI-301 in Patients With Advanced Malignancy

NCT06911008 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06911008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06911008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of SCD I: A First in Human Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of MTI-301 in Patients With Advanced Malignancy
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Recruiting
Start date
November 7, 2025
Completion date
April 9, 2027
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant solid neoplasm, refractory malignant solid neoplasm, unresectable malignant solid neoplasm